Castelnau Le Lez, France Clinical Trials

A listing of Castelnau Le Lez, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 14 clinical trials
Safety Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial

platelet count
Institut du Cancer de Montpellier - Val d'Aurelle
 (1.9 away) Contact site
  • 25 May, 2021
  • +3 other locations
Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

Stereo-Re-Pro aims to provide further evidence of Stereotactic Body Radiotherapy (SBRT) as a supplementary non-invasive curative treatment for local recurrence following radiotherapy. The objective of the first part of the trial (Phase I) is to select the recommended dose for salvage SBRT (either 5 x 6 Gy, 6 x 6 …

Institut r gional du Cancer de Montpellier
 (1.9 away) Contact site
  • 25 Jan, 2021
  • +14 other locations
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.

growth factor
platelet count
mantle cell lymphoma
H pital Saint-Eloi
 (7.5 away) Contact site
  • 07 May, 2021
  • +30 other locations
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

The purpose of this study is to evaluate the safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.

usher syndrome
usher syndrome type 2
spectral domain optical coherence tomography
genetic analysis
H pital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles G n tique
 (7.5 away) Contact site
  • 24 Jan, 2021
  • +7 other locations
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants …

Institut Regional du Cancer de Montpellier Val d'Aurelle
 (3.0 away) Contact site
  • 31 May, 2021
  • +83 other locations
A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

renal function
solid tumour
systemic therapy
ICM - Institut Regional du Cancer de Montpellier
 (1.9 away) Contact site
  • 14 May, 2021
  • +158 other locations
GEN3013 Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of epcoritamab GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH) and an expansion part phase 2a.

combination chemotherapy
renal function
refractory b-cell non-hodgkin lymphoma
marginal zone lymphoma
CHU Montpellier
 (1.9 away) Contact site
  • 24 Feb, 2021
  • +98 other locations
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.

platelet count
liver metastasis
Institut du Cancer Montpellier
 (1.9 away) Contact site
  • 27 Jan, 2021
  • +27 other locations
Safety Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer.

Institut R gional du Cancer de Montpellier
 (3.0 away) Contact site
  • 30 Apr, 2021
  • +15 other locations
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma

This study is a phase I/II, national, multicenter, open-label study starting with a Phase I part followed by a Phase II part. The phase I part of the study aims to evaluate the safety of the association of hypofractionated stereotactic radiation therapy (hFSRT) and the anti-PD-L1 Durvalumab immunotherapy in patients …

recurrent disease
platelet count
malignant glioma
measurable disease
Institut Regional Du Cancer de Montpellier
 (4.4 away) Contact site
  • 24 Jan, 2021
  • +9 other locations